BioSpace

BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat

In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma raised its full-year revenue forecast.

By BioSpace

1 min read
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights